List of Sponsors

Contact: 60064 North Chicago, United States of America, Kristina Bokenewicz, kristina.bokenewicz@abbvie.com, www.abbvie.com

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube, and LinkedIn.

Contact: 8045 Zurich, Switzerland

Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion developed and commercializes SOLIRIS® (eculizumab), the first and only approved complement inhibitor to treat patients with atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), refractory generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). As the global leader in complement inhibition, Alexion is leveraging its experience in complement biology to pursue novel molecules and targets in the complement cascade. Alexion’s development efforts focus the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care.

www.alexion.com 

Alnylam Pharmaceuticals

Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to help patients who have limited or inadequate treatment options live fuller, healthier lives. Founded in 2002 on the bold vision to turn scientific possibility into reality, Alnylam has a robust discovery platform and deep pipeline of investigational medicines, including several programs in late-stage clinical development.  Patients are at the core of everything we do; their needs drive our discoveries and their stories further our commitment to delivering innovative therapies.

For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam or on LinkedIn.
Contact: 6300 Zug, Switzerland, info@alnylam.com

Contact: 6300 Zug, Switzerland, Juan Vergez +41794671235, juan.vergez@arvelletx.com, www.arvelletx.com

Arvelle Therapeutics is an emerging biopharmaceutical company focused on bringing innovative solutions to patients with CNS disorders. Arvelle Therapeutics is responsible for the development and commercialization of cenobamate, an investigational anti-epileptic drug, in the European market. Arvelle Therapeutics is headquartered in Zug, Switzerland and is in the process of establishing a European footprint. For more details please visit: www.arvelletx.com 

 

Contact: À Av. Siderurgia Nacional, 4745-457 Coronado, Portugal, www.bial.com

Founded in 1924, BIAL's mission is to research, develop and provide therapeutic solutions within the area of health. In the last decades, BIAL has focused strategically on quality, innovation and internationalisation. BIAL is strongly committed to therapeutic innovation, investing more than 20% of its annual turnover into research and development within neurosciences and the cardiovascular system. The company expects to introduce new drugs on the market in the coming years, strengthening its international presence based on proprietary drugs and achieving its goal of supplying innovative products to patients worldwide. For more information on BIAL: www.bial.com 

Contact: 6340 Baar, Switzerland, Eva Hoff, switzerland.info@biogen.com, www.biogen.com

At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in multiple sclerosis and neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry, acute neurology, Alzheimer’s disease and dementia. Biogen also manufactures and commercializes biosimilars of advanced biologics. 

To learn more, please visit www.biogen.com 

Britannia Pharmaceuticals, part of the STADA Arzneimittel AG group of companies, is a UK based pharmaceutical company. We specialise in innovative products for chronic and serious medical conditions, and in particular, the treatment of Parkinson's disease. We are highly committed to improving the quality of life for People with Parkinson's disease.

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular and neuroscience. Our employees work every day to transform patients’ lives through science. 

Contact: 1214 Vernier-Geneve, Switzerland, www.lilly.com

 

About Eli Lilly and Company

Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels.

Contact: Cambridge, United Kingdom

GW Pharmaceuticals is a UK-based biopharmaceutical company that has established a world-leading position in cannabinoid science and medicine and was listed as one of TIME magazine’s ‘50 Genius Companies Inventing the Future, 2018’. Our mission is to unlock the potential of the cannabis plant through rigorous scientific investigations and extensive clinical trials, to improve the lives of seriously ill patients. Our pioneering work has led to the regulatory approval of world-first, potentially life-improving, cannabis-based medicines.1–3

Patients are our key focus, and improving their quality of life is our motivation.

Job code: VV-MED-17398
Date of preparation: January 2021

References
1.    US Food and Drug Administration (FDA). FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. 2018. Available from: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm611046.htm (Accessed 4 November 2020).
2.    European Medicines Agency (EMA). Epidyolex European public assessment report. 2018. Available from: www.ema.europa.eu/en/medicines/human/EPAR/epidyolex (Accessed 4 November 2020).
3.    Health Canada. Factsheet: Approval of SATIVEX® with Conditions. 2005. Available from: www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/conditions/fact-sheet-sativex.html (Accessed 4 November 2020).

 

Contact: 4070 Basel, Switzerland, +41616881111, basel.webmaster@roche.com, www.roche.com 

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

Contact: 4123, Allschwill, Switzerland, Ewelina Swierad, eswierad(at)its.jnj.com; www.janssen.com

About the Janssen Pharmaceutical Companies of Johnson & Johnson 

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenGlobal

Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.

Millions of people worldwide live with brain diseases, and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement, and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases – we call this Progress in Mind.

Read more at www.lundbeck.com/global/about-us/progress-in-mind

Our approximately 5,800 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing, and sales. Our pipeline consists of several R&D programs, and our products are available in more than 100 countries. We have research centers in Denmark and the US, and our production facilities are located in Denmark, France, and Italy. Lundbeck generated revenue of DKK 17 billion in 2019 (EUR 2.3 billion; USD 2.6 billion).

For additional information, we encourage you to visit our corporate site www.lundbeck.com, and connect with us on Twitter at @Lundbeck and via LinkedIn

 

Novartis is a leading global medicines company that is reimagining medicine to improve and extend people’s lives, using innovative science and digital technologies to create transformative treatments in areas of great medical need. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. Find out more at www.novartis.com.

Contact: EC4N 6EU London, United Kingdom, medinfo(at)orchard-tx.com

Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically-modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. The company has one of the deepest gene therapy product candidate pipelines in the industry and is advancing seven clinical-stage programs across multiple therapeutic areas, including inherited neurometabolic disorders, primary immune deficiencies and blood disorders, where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit www.orchard-tx.com, and follow us on Twitter and LinkedIn. 

Contact: NY 10017 New York, USA, +1 212-733-2323, info@Pfizer.com, www.pfizer.com

Pfizer Inc.: Breakthroughs that change patients’ lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com.

In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Contact:  www.sanofi.com

As the specialty care global business arm of Sanofi, Sanofi Genzyme is committed to meeting significant unmet medical needs. With a well-established heritage in multiple sclerosis, we continue to forge the way in neurology, seeking to provide hope where none existed before, developing innovative approaches to treatments based on patient insights, scientific expertise, and cutting-edge technology. By partnering with scientific, healthcare and patient communities, we continue to build on over 40 years of collaboration and inspiration, understanding and experience, empathy and knowledge to drive the development of potential new therapies and to help change what it means to live with a neurological disease. Learn more about these partnerships and possibilities at www.sanofi.com.  
MAT-GLB-2100089-2.0-01/2021

Contact: 1070 Brussels, Belgium, Laurent Schots, Tel: +32 2 559 99 99, Fax: +32 2 559 99 00, laurent.schots@ucb.comhttps://www.ucb.com

UCB (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. We are Inspired by Patients. Driven by Science. Follow us on Twitter: @UCB_news.